Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6262)	1/18/2005 9:21:43 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 10345

>>Seems to me (on strictly intuitive grounds) that Rebif will be the big loser. The driver to me seems to be time to antibody resistance. Rebif will* develop antibodies first, Betaseron next and then Avonex last. The development of antibodies correlates with efficacy but you give up longer term use by taking the stronger doses. That suggests that IF you were going to add an interferon to T it would be A. It also follows that R is the big loser. ij * based on averages and stats - there will be outliers.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next